The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
The role of cerebral amyloid β accumulation in common forms of Alzheimer disease
Open accessAbstract
For approximately 80 years following Alzheimer's description of the disease that bears his name, a gulf divided researchers who believed that extracellular deposits of the amyloid beta (Abeta) peptide were pathogenic from those who believed that the deposits were secondary detritus. Since 1990, the discoveries of missense mutations in the Abeta peptide precursor (APP) and the APP-cleaving enzyme presenilin 1 (PS1) have enabled much progress in understanding the molecular, cellular, and tissue pathology of the aggregates that accumulate in the interstices of the brains of patients with autosomal dominant familial Alzheimer disease (AD). Clarification of the molecular basis of common forms of AD has been more elusive. The central questions in common AD focus on whether cerebral and cerebrovascular Abeta accumulation is (a) a final neurotoxic pathway, common to all forms of AD; (b) a toxic by-product of an independent primary metabolic lesion that, by itself, is also neurotoxic; or (c) an inert by-product of an independent primary neurotoxic reaction. Antiamyloid medications are entering clinical trials so that researchers can evaluate whether abolition of cerebral amyloidosis can mitigate, treat, or prevent the dementia associated with common forms of AD. Successful development of antiamyloid medications is critical for elucidating the role of Abeta in common AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
Harper, J. D., & Lansbury, P. T. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.385 · Cited by 1,652
Wolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“org Volume 115 Number 5 May 2005 acute allergic encephalitis in 5% of 300 subjects (59), but phase I trials of passive immunization are now underway.”
BackgroundA subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“Aβ42 is inhibited while an otherwise trace species, Aβ38, is generated (60).”
BackgroundCorrelation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209
Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons
Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., & Simons, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6460 · Cited by 1,166
Huang, X., Atwood, C. S., Hartshorn, M. A., Multhaup, G., Goldstein, L. E., Scarpa, R. C., Cuajungco, M. P., Gray, D. N., Lim, J., Moir, R. D., et al. (1999) · Biochemistry · doi:10.1021/bi990438f · Cited by 1,107
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061
Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?
Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937
Buxbaum, J. D., Liu, K.-N., Luo, Y., Slack, J. L., Stocking, K. L., Peschon, J. J., Johnson, R. S., Castner, B. J., Cerretti, D. P., & Black, R. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.27765 · Cited by 934
Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T. M., Milton, S. C., Hall, J. E., & Glabe, C. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400260200 · Cited by 902
Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835
γ-Secretase-mediated proteolysis in cell-surface-receptor signalling
Fortini, M. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm910 · Cited by 824
Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10
Kojro, E., Gimpl, G., Lammich, S., März, W., & Fahrenholz, F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081612998 · Cited by 804
Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model
Refolo, L. M., Pappolla, M. A., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., & Duff, K. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0304 · Cited by 783
Praticò, D., Uryu, K., Leight, S., Trojanoswki, J. Q., & Lee, V. M.-Y. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04183.2001 · Cited by 777
Shoghi-Jadid, K., Small, G. W., Agdeppa, E. D., Kepe, V., Ercoli, L. M., Siddarth, P., Read, S., Satyamurthy, N., Petric, A., Huang, S.-C., et al. (2002) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200201000-00004 · Cited by 770
Miyata, M., & Smith, J. D. (1996) · Nature Genetics · doi:10.1038/ng0996-55 · Cited by 735
Postina, R., Schroeder, A., Dewachter, I., Bohl, J., Schmitt, U., Kojro, E., Prinzen, C., Endres, K., Hiemke, C., Blessing, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20864 · Cited by 638
Isoform-specific binding of apolipoprotein E to beta-amyloid.
LaDu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G. S., & Frail, D. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31529-6 · Cited by 540
Refolo, L. M., Pappolla, M. A., LaFrancois, J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., Tint, G. S., Wang, R., Mercken, M., Petanceska, S. S., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0422 · Cited by 521
Näslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A. D., Tjernberg, L. O., Silberring, J., Gandy, S. E., Winblad, B., & Greengard, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8378 · Cited by 468
Self-citationSparks, D. L., Scheff, S. W., Hunsaker, J. C., Liu, H., Landers, T., & Gross, D. R. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1044 · Cited by 443
The apolipoprotein ε4 allele in patients with Alzheimer's disease
Mayeux, R., Stern, Y., Ottman, R., Tatemichi, T. K., Tang, M., Maestre, G., Ngai, C., Tycko, B., & Ginsberg, H. (1993) · Annals of Neurology · doi:10.1002/ana.410340527 · Cited by 414
Treatment of Alzheimer's Disease
Mayeux, R., & Sano, M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911253412207 · Cited by 385
Protein phosphorylation regulates secretion of Alzheimer beta/A4 amyloid precursor protein.
Caporaso, G. L., Gandy, S. E., Buxbaum, J. D., Ramabhadran, T. V., & Greengard, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3055 · Cited by 339
Self-citationEvidence that Aβ42 is the real culprit in alzheimer's disease
Younkin, S. G. (1995) · Annals of Neurology · doi:10.1002/ana.410370303 · Cited by 333
Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide.
Buxbaum, J. D., Koo, E. H., & Greengard, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.9195 · Cited by 277
Mitchell, T. W., Mufson, E. J., Schneider, J. A., Cochran, E. J., Nissanov, J., Han, L., Bienias, J. L., Lee, V. M. ‐., Trojanowski, J. Q., Bennett, D. A., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10086 · Cited by 253
Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study
Li, G., Higdon, R., Kukull, W. A., Peskind, E., Van Valen Moore, K., Tsuang, D., van Belle, G., McCormick, W., Bowen, J. D., Teri, L., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000142963.90204.58 · Cited by 246
Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease
Praticò, D., & Sung, S. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6209 · Cited by 229
A novel presenilin 1 mutation associated with Pick's disease but not β‐amyloid plaques
Dermaut, B., Kumar‐Singh, S., Engelborghs, S., Theuns, J., Rademakers, R., Saerens, J., Pickut, B. A., Peeters, K., Van Den Broeck, M., Vennekens, K., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20083 · Cited by 212
Näslund, J., Thyberg, J., Tjernberg, L. O., Wernstedt, C., Karlström, A. R., Bogdanovic, N., Gandy, S. E., Lannfelt, L., Terenius, L., & Nordstedt, C. (1995) · Neuron · doi:10.1016/0896-6273(95)90079-9 · Cited by 189
Self-citationAPOE genotype, plasma lipids, lipoproteins, and AD in community elderly
Romas, S. N., Tang, M.-X., Berglund, L., & Mayeux, R. (1999) · Neurology · doi:10.1212/wnl.53.3.517 · Cited by 169
Amyloidosis and Alzheimer’s disease
Ghiso, J., & Frangione, B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00149-7 · Cited by 158
Modulation of Statin-Activated Shedding of Alzheimer APP Ectodomain by ROCK
Pedrini, S., Carter, T. L., Prendergast, G., Petanceska, S., Ehrlich, M. E., & Gandy, S. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020018 · Cited by 154
Self-citationMills, J., Laurent Charest, D., Lam, F., Beyreuther, K., Ida, N., Pelech, S. L., & Reiner, P. B. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-24-09415.1997 · Cited by 134
Alzheimer's Disease and Possible Gene Interaction
George‐Hyslop, P. S., McLachlan, D. C., Tsuda, T., Rogaev, E. I., Karlinsky, H., Lippa, C. F., & Pollen, D. A. (1994) · Science · doi:10.1126/science.8290965 · Cited by 132
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Qin, W., Ho, L., Pompl, P. N., Peng, Y., Zhao, Z., Xiang, Z., Robakis, N. K. R. K., Shioi, J., Suh, J., & Pasinetti, G. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307699200 · Cited by 113
Yang, D., Smith, J. D., Zhou, Z., Gandy, S. E., & Martins, R. N. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68020721.x · Cited by 111
Self-citationMartins, R. N., Clarnette, R., Fisher, C., Broe, G. A., Brooks, W. S., Montgomery, P., & Gandy, S. (1995) · Neuroreport · doi:10.1097/00001756-199507310-00012 · Cited by 105
Self-citationYao, Y., Chinnici, C. M., Tang, H., Trojanowski, J. Q., Lee, V. M. ‐., & Praticò, D. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-21 · Cited by 91
Zhou, Z., Smith, J. D., Greengard, P., & Gandy, S. (1996) · Molecular Medicine · doi:10.1007/bf03401614 · Cited by 79
Self-citationPäiviö, A., Jarvet, J., Gräslund, A., Lannfelt, L., & Westlind‐Danielsson, A. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.03.028 · Cited by 77
Zhou, Z., Smith, J. D., Greengard, P., & Gandy, S. (1996) · PubMed Central · Cited by 71
Self-citationAlford, M. F., Masliah, E., Hansen, L. A., & Terry, R. D. (1994) · Journal of Histochemistry & Cytochemistry · doi:10.1177/42.2.8288869 · Cited by 66
Prostaglandin H2 (PGH2) accelerates formation of amyloid β1−42 oligomers
Boutaud, O. G., Ou, J. J., Chaurand, P., Caprioli, R. M., Montine, T. J., & Oates, J. A. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01064.x · Cited by 58
Calingasan, N. Y., Gandy, S., Baker, H., Sheu, K. R., Smith, J. D., Lamb, B. T., Gearhart, J. D., Buxbaum, J. D., Harper, C. C., Selkoe, D. J., et al. (1996) · Europe PMC (PubMed Central) · Cited by 56
Self-citationYao, J., Petanceska, S. S., Montine, T. J., Holtzman, D. M., Schmidt, S. D., Parker, C. A., Callahan, M. J., Lipinski, W. J., Bisgaier, C. L., Turner, B. A., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02532.x · Cited by 41
Self-citationLarwood, V., Webb, G. A., & Howlin, B. J. (1996) · Journal of Molecular Modeling · doi:10.1007/s0089460020175 · Cited by 40
Neurohormonal Signaling Pathways and the Regulation of Alzheimer β-Amyloid Precursor Metabolism
Gandy, S. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(99)00166-6 · Cited by 35
Self-citationPresenilin mutations associated with fronto‐temporal dementia
Hutton, M. L. (2004) · Annals of Neurology · doi:10.1002/ana.20103 · Cited by 28
Zhou, Z., Relkin, N. R., Ghiso, J. A., Smith, J. D., & Gandy, S. (2002) · Molecular Medicine · doi:10.1007/bf03402018 · Cited by 6
Self-citationSimilar promotion of Aβ1-42 fibrillogenesis by native apolipoprotein E ε3 and ε4 isoforms
Sweeney, D. A., Martins, R. N., LeVine, H., Smith, J. D., & Gandy, S. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-15 · Cited by 5
Self-citation
Cited by
Alzheimer's Disease: From Pathology to Therapeutic Approaches
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802808 · Cited by 626
Bioactive Benzofuran derivatives: A review
Khanam, H., & Shamsuzzaman (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.039 · Cited by 554
Lee, W.-H., Loo, C.-Y., Bebawy, M., Luk, F., Mason, R., & Rohanizadeh, R. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311040002 · Cited by 537
The Role of NADPH Oxidases and Oxidative Stress in Neurodegenerative Disorders
Tarafdar, A., & Pula, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123824 · Cited by 373
Microglia-Mediated Synapse Loss in Alzheimer's Disease
Rajendran, L., & Paolicelli, R. C. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1136-17.2017 · Cited by 355
Metadata
- Authors
- Gandy, S.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-05-02
- Volume
- 115
- Issue
- 5
- Pages
- 1121-1129
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2043392060
- Cited by
- 385
- References
- 61
- FWCI
- 14.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.